drugset / Trial / NCT01619345

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

NCT01619345

Phase 1 Completed 27 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.

Timeline

Start
2012-06
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Background Semaglutide Peptide 10 mg

Indications